Type I PRMT inhibition protects against C9ORF72 arginine-rich dipeptide repeat toxicity

Alan Premasiri(Amyotrophic Lateral Sclerosis Therapy Development Institute), Fernando G. Vieira(Amyotrophic Lateral Sclerosis Therapy Development Institute)
bioRxiv (Cold Spring Harbor Laboratory)
May 22, 2020
10.1101/2020.05.20.106260
Cited by 2

Related Papers

Design, power, and interpretation of studies in the standard murine model of ALS
|Amyotrophic Lateral Sclerosis|2008|502
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
|Nature Medicine|2025|85